Stay updated on Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial page
- Check2 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3. The visible study content and links remain unchanged.SummaryDifference0.1%

- Check10 days agoChange DetectedLung cancer and the MedlinePlus Genetics related topics were removed from the page.SummaryDifference0.2%

- Check17 days agoChange DetectedAdded related topics Lung cancer and MedlinePlus Genetics to the related topics section.SummaryDifference0.2%

- Check31 days agoChange DetectedAdded Revision: v3.4.2; removed the funding-status notice and related topic links (Lung cancer and MedlinePlus Genetics), and removed Revision: v3.4.1.SummaryDifference0.6%

- Check38 days agoChange DetectedSite-wide notice about a lapse in government funding and operating status was added, and the page revision updated to v3.4.1. The core study content and criteria remain unchanged.SummaryDifference0.4%

- Check45 days agoChange DetectedAdded a glossary toggle (Show glossary) and updated UI text, standardizing labels such as 'Last Update Submitted that Met QC Criteria' and capitalization of 'No FEAR Act Data'. The revision/version banner now shows v3.4.0 (replacing v3.3.4); To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial page.